## **NICE** National Institute for Health and Care Excellence

## Urinary tract infections in under 16 guideline committee 1 meeting minutes

## UTI in under 16s Guideline Update – Committee Meeting 1

**Date:** 08/03/2022

Location: Virtual

Minutes: Final

## Committee members present:

Tessa Lewis (Chair) (TL)	Present for notes 1 – 7
Stephanie Dancer	Present for notes 1 – 7
Callum Douglass	Present for notes 1 – 7
Stuart Hartshorn	Present for notes 1 – 7
Ian Hill-Smith	Present for notes 1 – 7
Philip Howard	Present for notes 1 – 6
Annie Joseph	Present for notes 1 – 7
Fatima Kagalwala	Present for notes 1 – 7
Marisa Lanzman	Present for notes 1 – 7
Paddy McMaster	Present for notes 1 – 7
John Morris	Present for notes 1 – 7
Mitul Patel	Present for notes 1 – 7
Carole Pitkeathley	Present for notes 1 – 7
David Spitzer	Present for notes 1 – 7
Alison Taylor	Present for notes 1 – 7
Clare Titley	Present for notes 1 – 7
Avril Tucker	Present for notes 1 – 7
Caroline Ward	Present for notes 1 – 7

r notes 1 – 7
r notes 1 – 7
r notes 5 – 7

## Urinary tract infections in under 16 guideline committee 1 meeting minutes

Kate Kelley	Associate Director, Guideline Development Team	
Erin Whittingham	Public Involvement Programme Lead	

## 1. Welcome and objectives for the meeting

The Chair (TL) welcomed the committee members and NICE attendees to the first UTI guideline committee meeting.

TL then informed the committee that apologies had been received which are noted above.

TL then outlined the objectives of the meeting before asking all committee members to verbally declare any interests that have arisen since the last meeting.

Name	Job title,	Declarations of Interest,	Type of	Decision
	organisation	date declared	interest	taken
Annie Joseph	Consultant Microbiologist - PHAC D Advisory Committee Member	Received sponsorship from Eumedica to attend European Congress of Clinical Microbiology and Infectious Diseases 2022 - https://www.eccmid.org/	Direct Financial	Declare and participate - Attendance only, Not giving speeches or presentations.

TL and senior members of the Developer team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

#### 2. Revisiting methods and presenting clinical evidence

TL introduced Marie Harrisingh (MH) and Gregory Moran (GM) who took the committee through a brief presentation to revisit the methods for this update.

GM then gave a further presentation on clinical evidence, covering the update's place in the diagnostic pathway and an overview of included studies.

#### 3. Clinical evidence presentation (continued)

After a short break, GM and MH continued their presentation of the clinical evidence for this update, covering included studies, study limitations and results.

#### 4. Clinical evidence presentation (continued) and health economics

GM and MH continued their presentation on the clinical evidence. This time covering diagnostic models.

# TL thanked MH and GM for their presentation and closed this section of the meeting **5. Drafting recommendations**

For the afternoon session, TL introduced MH and GM, who began the discussion on the proposed recommendations for this update.

The committee were shown the existing recommendations and the suggested changes the development team had drafted and asked for feedback.

### 6. Drafting recommendations (continued)

## Urinary tract infections in under 16 guideline committee 1 meeting minutes

For the final portion of the day, MH and GM continued to present on the proposed recommendations.

JD also joined them to provide a brief presentation health economics discussion.

The committee discussed the recommendations and provided their suggested changes and additions. TL thanked them for their input, and MH, JD and GM for their hard work in preparing these presentations and closed this section of the meeting.

#### 7. AOB, Summary and next steps

JL advised the committee of the next steps and key dates in development leading up to the consultation on this guideline, including that they would be sent redrafts of the recommendations and evidence review, with changes based on their comments and feedback at the meeting.

TL thanked everyone for their attendance and closed the meeting.

Date of next meeting: 16/05/2022 (TBC)

Location of next meeting: Virtual